Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-587101 in Moderate to Severe Psoriasis
NCT00162253Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing BMS-587101 with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving PASI 50. Started Apr 2005; status: terminated.
02
Drugs
BMS-587101
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00162253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162253.